In vitro inhibition of cytochrome P450 activities by active constituents of Chinese herbal drugs

Chinese Pharmacological Bulletin

Volumn 27, Issue 4, 2011, Pages 519-523

  Ai, Chang Hong ^a,b   Sun, Han Xiong ^a   Li, Hua ^a   Zhuang, Xiao Mei ^a   Dong, De Li ^b  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cocktail substrate assay; Cytochrome P450; Drug drug interaction; Herbal active constituents; Inhibition; Liver microsomes

Indexed keywords

BERBERINE; CAMPTOTHECIN; CHINESE DRUG; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOSINE; HERBACEOUS AGENT; ISOENZYME; ISOPROTEIN; ISORHAMNETIN; MIDAZOLAM; NARINGENIN; OLEANOLIC ACID; PHENACETIN O DEETHYLASE; PROTEIN INHIBITOR; RHEIN;

ARTICLE; ASSAY; CLINICAL EVALUATION; DRUG ANALYSIS; DRUG INTERACTION; DRUG METABOLISM; IC 50; IN VITRO STUDY; LIVER MICROSOME; NONHUMAN; VALIDATION PROCESS;

EID: 79960084433     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1001-1978.2011.04.019     Document Type: Article

References (15)

1. Williamson E M. Drug interactions between herbal and prescription medicines[J]. Drug Safety, 2003,26(15):1075-92. (Pubitemid 38021390)
2. Izzo A A, Ernst E. Interactions between herbal medicines and prescribed drugs [J]. Drugs, 2009,69(13):1777-98.
3. Li T J, Hong Z F, Zhou J H. Research progression on regulation of liver drug metabolic enzymes by herbal active constituents[J]. J Fujian Coll TCM, 2006,16(3):70-2
4. Bush T M, Raybum K S, Holloway S W, et al. Adverse interactions between herbal and dietary substances and prescription medications: a clinical survey[J]. Alternat Ther Health Med, 2007,13 (2):30-5. (Pubitemid 46427630)
5. Guo Y, Wang H. Study of probe substrate specificity for human cytochrome P450 isoenzymes[J]. Chin Pharmacol Bull, 2007,23 (7):851-4. (Pubitemid 47555780)
6. Lin Q H, Zhuang X M, Deng J T, et al. Metabolic interaction between rotundine and oxycodone in vitro [J]. Chin J Pharmacol Toxicol, 2009,23(5):404-10.
7. Yao M, Zhu M, Sinz M W, et al. Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis[J]. J Pharm Biomed Anal, 2007,44(1):211-23. (Pubitemid 46551606)
8. Parmentier Y, Bossant M J, Bertrand M, et al. In vitro studies of drug metabolism[ M]// Testa B, van de Waterbeemd H. Comprehensive Medicinal Chemistry II-ADME-Tox Approaches. Beijing: Science Press, 2007:246.
9. US FDA. Guidance for industry: Drug interaction studies-study design, data analysis, and implications for dosing and labeling [EB/OL]. [2010 - 10 - 29] http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm072101.pdf
10. Bjornsson T D, Callaghan J T, Einolf H J, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRAM) perspective[J]. Drug Metab Dispos, 2003,31(7):815-32. (Pubitemid 36759050)
11. Fan L, Peng X D, Guo Z H, Zhou H H. Genetic polymorphism of cytochrome P450 oxidoreductase and its effect on drug metabolism [J]. Chin Pharmacol Bull, 2009,25(9):1131-3.